uPA/uPAR and SERPINE1 in head and neck cancer: Role in tumor resistance, metastasis, prognosis and therapy

Oncotarget

Volumn 7, Issue 35, 2016, Pages 57351-57366

  Pavón, Miguel Angel ^a,b,c   Arroyo Solera, Irene ^a,c   Céspedes, Maria Virtudes ^a,c   Casanova, Isolda ^a,c   León, Xavier ^c,d   Mangues, Ramón ^a,c  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Head and neck cancer; Prognosis; SERPINE1; UPA; UPAR

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; TUMOR MARKER; UROKINASE; UROKINASE RECEPTOR; SERPINE1 PROTEIN, HUMAN;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STEM CELL; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; DISEASE ASSOCIATION; DRUG RESISTANCE; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR CELL; TUMOR INVASION; TUMOR VASCULARIZATION; ANIMAL; GENE EXPRESSION PROFILING; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84984918509     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.10344     Document Type: Review

References (162)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9-29.
2. Leemans CR, Braakhuis BJ and BrakenhoffRH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011; 11:9-22.
3. Licitra L, Mesia R and Keilholz U. Individualised quality of life as a measure to guide treatment choices in squamous cell carcinoma of the head and neck. Oral Oncol. 2015.
4. Leon X, Martinez V, Lopez M, Garcia J, Venegas Mdel P, Esteller E and Quer M. Second, third, and fourth head and neck tumors. A progressive decrease in survival. Head Neck. 2012; 34:1716-1719.
5. Licitra L and Vermorken JB. Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol. 2004; 15:7-11.
6. Wang HY, Chang YL, To KF, Hwang JS, Mai HQ, Feng YF, Chang ET, Wang CP, Kam MK, Cheah SL, Lee M, Gao L, Zhang HZ, He JH, Jiang H, Ma PQ, et al. A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chinese journal of cancer. 2016; 35:41.
7. Shen LJ, Wang SY, Xie GF, Zeng Q, Chen C, Dong AN, Huang ZM, Pan CC, Xia YF and Wu PH. Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system. Chinese journal of cancer. 2015; 34:450-458.
8. Lun SW, Cheung ST and Lo KW. Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chinese journal of cancer. 2014; 33:529-538.
9. Takes RP, Rinaldo A, Rodrigo JP, Devaney KO, Fagan JJ and Ferlito A. Can biomarkers play a role in the decision about treatment of the clinically negative neck in patients with head and neck cancer? Head Neck. 2008; 30:525-538.
10. Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R and Masarik M. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014; 50:168-177.
11. da Silva SD, Ferlito A, Takes RP, BrakenhoffRH, Valentin MD, Woolgar JA, Bradford CR, Rodrigo JP, Rinaldo A, Hier MP and Kowalski LP. Advances and applications of oral cancer basic research. Oral Oncol. 2011; 47:783-791.
12. Andreasen PA, Kjoller L, Christensen L and Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer. 1997; 72:1-22.
13. Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des. 2004; 10:39-49.
14. Blasi F and Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002; 3:932-943.
15. Van De Craen B, Declerck PJ and Gils A. The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo. Thromb Res. 2012; 130:576-585.
16. Simone TM, Longmate WM, Law BK and Higgins PJ. Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. Adv Wound Care (New Rochelle). 2015; 4:321-328.
17. Simone TM and Higgins PJ. Inhibition of SERPINE1 Function Attenuates Wound Closure in Response to Tissue Injury: A Role for PAI-1 in Re-Epithelialization and Granulation Tissue Formation Journal of Developmental Biology. 2015; 3:11-24.
18. McMahon BJ and Kwaan HC. Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer. Adv Exp Med Biol. 2015; 867:145-156.
19. Dass K, Ahmad A, Azmi AS, Sarkar SH and Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev. 2008; 34:122-136.
20. Behrens MA, Botkjaer KA, Goswami S, Oliveira CL, Jensen JK, Schar CR, Declerck PJ, Peterson CB, Andreasen PA and Pedersen JS. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. J Mol Biol. 2011; 411:417-429.
21. Andreasen PA, Egelund R and Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000; 57:25-40.
22. Shi Z and Stack MS. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J. 2007; 407:153-159.
23. Kwaan HC, Mazar AP and McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost. 2013; 39:382-391.
24. McMahon B and Kwaan HC. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb. 2008; 36:184-194.
25. Jo M, Takimoto S, Montel V and Gonias SL. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. The American journal of pathology. 2009; 175:190-200.
26. Petruzzelli GJ, Snyderman CH and Johnson JT. In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg. 1994; 120:989-992.
27. Nozaki S, Endo Y, Kawashiri S, Nakagawa K, Yamamoto E, Yonemura Y and Sasaki T. Immunohistochemical localization of a urokinase-type plasminogen activator system in squamous cell carcinoma of the oral cavity: association with mode of invasion and lymph node metastasis. Oral Oncol. 1998; 34:58-62.
28. Li HF, Liu YQ, Shen ZJ, Gan XF, Han JJ, Liu YY, Li HG and Huang ZQ. Downregulation of MACC1 inhibits invasion, migration and proliferation, attenuates cisplatin resistance and induces apoptosis in tongue squamous cell carcinoma. Oncol Rep. 2015; 33:651-660.
29. Farahani E, Patra HK, Jangamreddy JR, Rashedi I, Kawalec M, Rao Pariti RK, Batakis P and Wiechec E. Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis. 2014; 35:747-759.
30. Aguirre Ghiso JA, Kovalski K and Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999; 147:89-104.
31. Aguirre Ghiso JA. Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo. Oncogene. 2002; 21:2513-2524.
32. Albo D and Tuszynski GP. Thrombospondin-1 up-regulates tumor cell invasion through the urokinase plasminogen activator receptor in head and neck cancer cells. J Surg Res. 2004; 120:21-26.
33. Rosenthal EL, Hotary K, Bradford C and Weiss SJ. Role of membrane type 1-matrix metalloproteinase and gelatinase A in head and neck squamous cell carcinoma invasion in vitro. Otolaryngol Head Neck Surg. 1999; 121:337-343.
34. Shimada T, Nakamura H, Yamashita K, Kawata R, Murakami Y, Fujimoto N, Sato H, Seiki M and Okada Y. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinomas: implications for lymph node metastasis. Clin Exp Metastasis. 2000; 18:179-188.
35. Gorogh T, Beier UH, Baumken J, Meyer JE, Hoffmann M, Gottschlich S and Maune S. Metalloproteinases and their inhibitors: influence on tumor invasiveness and metastasis formation in head and neck squamous cell carcinomas. Head Neck. 2006; 28:31-39.
36. Zhou H, Tang Y, Liang X, Yang X, Yang J, Zhu G, Zheng M and Zhang C. RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. Int J Cancer. 2009; 125:453-462.
37. Ghosh S, Koblinski J, Johnson J, Liu Y, Ericsson A, Davis JW, Shi Z, Ravosa MJ, Crawford S, Frazier S and Stack MS. Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression. Mol Cancer Res. 2010; 8:145-158.
38. Smith HW and Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010; 11:23-36.
39. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, Clayman GL, Adler-Storthz K and Chen Z. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer. 2002; 95:1663-1672.
40. Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, Yan YP, Zheng LS, Xie P, Cao Y, Liang YY, Zheng FJ, Huang BJ, Xiang YQ, Lv X, Chen QY, et al. Urokinasetype plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014; 13:1958-1969.
41. Nozaki S, Endo Y, Nakahara H, Yoshizawa K, Hashiba Y, Kawashiri S, Tanaka A, Nakagawa K, Matsuoka Y, Kogo M and Yamamoto E. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. Oral Oncol. 2005; 41:971-977.
42. Ignar DM, Andrews JL, Witherspoon SM, Leray JD, Clay WC, Kilpatrick K, Onori J, Kost T and Emerson DL. Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clin Exp Metastasis. 1998; 16:9-20.
43. Wang S, Cao Q, Wang X, Li B, Tang M, Yuan W, Fang J, Qian J, Qin C and Zhang W. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from metaanalysis. PLoS One. 2013; 8:e56797.
44. Kortlever RM, Higgins PJ and Bernards R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol. 2006; 8:877-884.
45. Fink T, Kazlauskas A, Poellinger L, Ebbesen P and Zachar V. Identification of a tightly regulated hypoxia-response element in the promoter of human plasminogen activator inhibitor-1. Blood. 2002; 99:2077-2083.
46. Ulisse S, Baldini E, Sorrenti S and D'Armiento M. The urokinase plasminogen activator system: a target for anticancer therapy. Curr Cancer Drug Targets. 2009; 9:32-71.
47. Gao S, Skeldal S, Krogdahl A, Sorensen JA and Andreasen PA. CpG methylation of the PAI-1 gene 5'-flanking region is inversely correlated with PAI-1 mRNA levels in human cell lines. Thromb Haemost. 2005; 94:651-660.
48. Gao S, Nielsen BS, Krogdahl A, Sorensen JA, Tagesen J, Dabelsteen S, Dabelsteen E and Andreasen PA. Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer. 2010; 49:526-538.
49. Cao P, Zhou L, Zhang J, Zheng F, Wang H, Ma D and Tian J. Comprehensive expression profiling of microRNAs in laryngeal squamous cell carcinoma. Head Neck. 2013; 35:720-728.
50. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, Hansen TB, Jensen TI, Borre M, Orntoft TF, Dyrskjot L and Kjems J. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer. 2012; 106:366-374.
51. Gotte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M, Ibrahim SA, Peddibhotla S, Teng YH, Low JY, Ebnet K, Kiesel L and Yip GW. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 2010; 29:6569-6580.
52. Sun ZJ, Yu GT, Huang CF, Bu LL, Liu JF, Ma SR, Zhang WF, Liu B and Zhang L. Hypoxia induce TFE3 expression in head and neck squamous cell carcinoma. Oncotarget. 2016; doi: 10.18632/oncotarget.7309.
53. Gils A and Declerck PJ. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors. Thromb Haemost. 2004; 91:425-437.
54. Declerck PJ, De Mol M, Vaughan DE and Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem. 1992; 267:11693-11696.
55. Harbeck N, Kates RE, Gauger K, Willems A, Kiechle M, Magdolen V and Schmitt M. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer. Thromb Haemost. 2004; 91:450-456.
56. Duffy MJ, McGowan PM and Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol. 2008; 214:283-293.
57. Lee C and Huang T. Plasminogen Activator Inhibitor-1: The Expression, Biological Functions, and Effects on Tumorigenesis and Tumor Cell Adhesion and Migration. Journal of Cancer Molecules. 2005; 1:25-36.
58. Wilkins-Port CE, Ye Q, Mazurkiewicz JE and Higgins PJ. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Cancer Res. 2009; 69:4081-4091.
59. Higgins SP, Samarakoon R, Higgins CE, Freytag J, Wilkins-Port CE and Higgins PJ. TGF-beta1-Induced Expression of the Anti-Apoptotic PAI-1 Protein Requires EGFR Signaling. Cell Commun Insights. 2009; 2:1-11.
60. Samarakoon R, Higgins CE, Higgins SP and Higgins PJ. TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy. J Oncol. 2009; 2009:342391.
61. Dhanda J, Triantafyllou A, Liloglou T, Kalirai H, Lloyd B, Hanlon R, Shaw RJ, Sibson DR and Risk JM. SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma. Br J Cancer. 2014; 111:2114-2121.
62. Pavon MA, Arroyo-Solera I, Tellez-Gabriel M, Leon X, Viros D, Lopez M, Gallardo A, Cespedes MV, Casanova I, Lopez-Pousa A, Mangues MA, Quer M, Barnadas A and Mangues R. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget. 2015; 6:29016-29033. doi: 10.18632/oncotarget.5032.
63. Balsara RD, Castellino FJ and Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem. 2006; 281:22527-22536.
64. Webb DJ, Thomas KS and Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol. 2001; 152:741-752.
65. Langlois B, Perrot G, Schneider C, Henriet P, Emonard H, Martiny L and Dedieu S. LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One. 2010; 5:e11584.
66. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y and LoskutoffDJ. The low density lipoprotein receptorrelated protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem. 2004; 279:22595-22604.
67. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D and Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998; 4:923-928.
68. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA and DeClerck YA. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell. 2008; 14:324-334.
69. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA and Castellino FJ. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res. 2000; 60:5839-5847.
70. Jing Y, Kovacs K, Kurisetty V, Jiang Z, Tsinoremas N and Merchan JR. Role of plasminogen activator inhibitor-1 in urokinase's paradoxical in vivo tumor suppressing or promoting effects. Mol Cancer Res. 2012; 10:1271-1281.
71. Gonias SL and Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015; 6:154.
72. Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y, Shih CC and Aboody KS. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. PLoS One. 2007; 2:e243.
73. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N, Klijn JG and Foekens JA. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. 2004; 64:4563-4568.
74. Eastman BM, Jo M, Webb DL, Takimoto S and Gonias SL. A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen. Cell Signal. 2012; 24:1847-1855.
75. Schilling D, Bayer C, Geurts-Moespot A, Sweep FC, Pruschy M, Mengele K, Sprague LD and Molls M. Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. BMC Cancer. 2007; 7:143.
76. Artman T, Schilling D, Gnann J, Molls M, MulthoffG and Bayer C. Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck. Int J Radiat Oncol Biol Phys. 2010; 76:574-582.
77. Bayer C, Kielow A, Schilling D, Maftei CA, Zips D, Yaromina A, Baumann M, Molls M and MulthoffG. Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation. Int J Radiat Oncol Biol Phys. 2012; 84:e409-417.
78. Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom RC and Roberg K. Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther. 2010; 10:1244-1251.
79. Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y and Yamagishi H. Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer. 2004; 91:1543-1550.
80. Lee YC, Yu CC, Lan C, Lee CH, Lee HT, Kuo YL, Wang PH and Chang WW. Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers. Head Neck. 2015.
81. Wykosky J, Hu J, Gomez GG, Taylor T, Villa GR, Pizzo D, VandenBerg SR, Thorne AH, Chen CC, Mischel PS, Gonias SL, Cavenee WK and Furnari FB. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2015; 75:394-404.
82. Abu-Ali S, Fotovati A and Shirasuna K. Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. Mol Cancer. 2008; 7:47.
83. Waldron NN, Oh S and Vallera DA. Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma. Oral Oncol. 2012; 48:1202-1207.
84. Huang Z, Li H, Huang Q, Chen D, Han J, Wang L, Pan C, Chen W, House MG, Nephew KP and Guo Z. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer. Mol Carcinog. 2014; 53:777-786.
85. Soeda S, Koyanagi S, Kuramoto Y, Kimura M, Oda M, Kozako T, Hayashida S and Shimeno H. Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system. Thromb Haemost. 2008; 100:1014-1020.
86. Schneider DJ, Chen Y and Sobel BE. The effect of plasminogen activator inhibitor type 1 on apoptosis. Thromb Haemost. 2008; 100:1037-1040.
87. Fang H, Placencio VR and DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst. 2012; 104:1470-1484.
88. Romer MU, Larsen L, Offenberg H, Brunner N and Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia. 2008; 10:1083-1091.
89. Lademann UA and Romer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost. 2008; 100:1041-1046.
90. Czekay RP, Wilkins-Port CE, Higgins SP, Freytag J, Overstreet JM, Klein RM, Higgins CE, Samarakoon R and Higgins PJ. PAI-1: An Integrator of Cell Signaling and Migration. Int J Cell Biol. 2011; 2011:562481.
91. Simone TM, Higgins CE, Czekay RP, Law BK, Higgins SP, Archambeault J, Kutz SM and Higgins PJ. SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-"Activated" Keratinocytes. Adv Wound Care (New Rochelle). 2014; 3:281-290.
92. Fedotov S and Iomin A. Migration and proliferation dichotomy in tumor-cell invasion. Phys Rev Lett. 2007; 98:118101.
93. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
94. Smith A, Teknos TN and Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013; 49:287-292.
95. Gemenetzidis E, Gammon L, Biddle A, Emich H and Mackenzie IC. Invasive oral cancer stem cells display resistance to ionising radiation. Oncotarget. 2015; 6:43964-43977 doi: 10.18632/oncotarget.6268.
96. Aneta G, Tomas V, Daniel R and Jan B. Cell polarity signaling in the plasticity of cancer cell invasiveness. Oncotarget. 2016; doi: 10.18632/oncotarget.7214.
97. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, IsakoffSJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013; 339:580-584.
98. Datta PK, Blake MC and Moses HL. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between smads and Sp1. J Biol Chem. 2000; 275:40014-40019.
99. Liu K, Lin B, Zhao M, Yang X, Chen M, Gao A, Liu F, Que J and Lan X. The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal. 2013; 25:1264-1271.
100. Yu XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, Somnay YR, Leverson G, Sippel RS, Lloyd RV, Johnson BP and Chen H. Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression. Clin Cancer Res. 2016.
101. Sakamoto K, Fujii T, Kawachi H, Miki Y, Omura K, Morita K, Kayamori K, Katsube K and Yamaguchi A. Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms. Lab Invest. 2012; 92:688-702.
102. BrakenhoffRH. Cancer. Another NOTCH for cancer. Science. 2011; 333:1102-1103.
103. Proweller A, Tu L, Lepore JJ, Cheng L, Lu MM, Seykora J, Millar SE, Pear WS and Parmacek MS. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006; 66:7438-7444.
104. Okuyama R, Nguyen BC, Talora C, Ogawa E, Tommasi di Vignano A, Lioumi M, Chiorino G, Tagami H, Woo M and Dotto GP. High commitment of embryonic keratinocytes to terminal differentiation through a Notch1-caspase 3 regulatory mechanism. Dev Cell. 2004; 6:551-562.
105. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, Miele L, Aguet M, Radtke F and Dotto GP. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001; 20:3427-3436.
106. Jo M, Lester RD, Montel V, Eastman B, Takimoto S and Gonias SL. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling. J Biol Chem. 2009; 284:22825-22833.
107. Tsai JH and Yang J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013; 27:2192-2206.
108. De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, Locati L, Licitra L and Canevari S. Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data. Oncotarget. 2015; 6:9627-9642. doi: 10.18632/oncotarget.3301.
109. Pavon MA, Parreno M, Tellez-Gabriel M, Sancho FJ, Lopez M, Cespedes MV, Casanova I, Lopez-Pousa A, Mangues MA, Quer M, Barnadas A, Leon X and Mangues R. Gene expression signatures and molecular markers associated with clinical outcome in locally advanced head and neck carcinoma. Carcinogenesis. 2012; 33:1707-1716.
110. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG and Perou CM. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5:489-500.
111. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, Tilanus MG, Koole R, Hordijk GJ, van der Vliet PC, Reinders MJ, Slootweg PJ and Holstege FC. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet. 2005; 37:182-186.
112. Jo M, Eastman BM, Webb DL, Stoletov K, Klemke R and Gonias SL. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res. 2010; 70:8948-8958.
113. Asuthkar S, Stepanova V, Lebedeva T, Holterman AL, Estes N, Cines DB, Rao JS and Gondi CS. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell. 2013; 24:2620-2632.
114. Clayman G, Wang SW, Nicolson GL, el-Naggar A, Mazar A, Henkin J, Blasi F, Goepfert H and Boyd DD. Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. Int J Cancer. 1993; 54:73-80.
115. Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS and Bugge TH. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography. Oral Oncol. 2004; 40:1026-1032.
116. Lindberg P, Larsson A and Nielsen BS. Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma. Int J Cancer. 2006; 118:2948-2956.
117. Pasini FS, Brentani MM, Kowalski LP and Federico MH. Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa. Head Neck. 2001; 23:725-732.
118. Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA and Berns EM. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck. 2007; 29:341-350.
119. He Y, Shao F, Pi W, Shi C, Chen Y, Gong D, Wang B, Cao Z and Tang K. Largescale Transcriptomics Analysis Suggests Over-Expression of BGH3, MMP9 and PDIA3 in Oral Squamous Cell Carcinoma. PLoS One. 2016; 11:e0146530.
120. Bagordakis E, Sawazaki-Calone I, Macedo CC, Carnielli CM, de Oliveira CE, Rodrigues PC, Rangel AL, Dos Santos JN, Risteli J, Graner E, Salo T, Leme AF and Coletta RD. Secretome profiling of oral squamous cell carcinomaassociated fibroblasts reveals organization and disassembly of extracellular matrix and collagen metabolic process signatures. Tumour Biol. 2016.
121. Mendez E, Houck JR, Doody DR, Fan W, Lohavanichbutr P, Rue TC, Yueh B, Futran ND, Upton MP, Farwell DG, Heagerty PJ, Zhao LP, Schwartz SM and Chen C. A genetic expression profile associated with oral cancer identifies a group of patients at high risk of poor survival. Clin Cancer Res. 2009; 15:1353-1361.
122. Liu CJ, Liu TY, Kuo LT, Cheng HW, Chu TH, Chang KW and Lin SC. Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J Pathol. 2008; 214:489-497.
123. Schmalbach CE, Chepeha DB, Giordano TJ, Rubin MA, Teknos TN, Bradford CR, Wolf GT, Kuick R, Misek DE, Trask DK and Hanash S. Molecular profiling and the identification of genes associated with metastatic oral cavity/pharynx squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2004; 130:295-302.
124. Strojan P, Budihna M, Smid L, Vrhovec I and Skrk J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur J Cancer. 1998; 34:1193-1197.
125. Zaravinos A. An updated overview of HPV-associated head and neck carcinomas. Oncotarget. 2014; 5:3956-3969. doi: 10.18632/oncotarget.1934.
126. Fakhry C, Psyrri A and Chaturvedhi A. HPV and head and neck cancers: state-of-the-science. Oral Oncol. 2014; 50:353-355.
127. Yasuda T, Sakata Y, Kitamura K, Morita M and Ishida T. Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck. Head Neck. 1997; 19:611-616.
128. Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman WB. Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 2005; 113:789-797.
129. Huang CF, Yu GT, Wang WM, Liu B and Sun ZJ. Prognostic and predictive values of SPP1, PAI and caveolin-1 in patients with oral squamous cell carcinoma. Int J Clin Exp Pathol. 2014; 7:6032-6039.
130. Magnussen S, Rikardsen OG, Hadler-Olsen E, Uhlin-Hansen L, Steigen SE and Svineng G. Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC). PLoS One. 2014; 9:e101895.
131. Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C and Horch HH. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity-clinical relevance and prognostic value. J Craniomaxillofac Surg. 2005; 33:191-196.
132. Inoue Y, Sugiura T, Matsuki R, Ishii K, Seki K and Shirasuna K. Plaminogen Activator Inhibitor-1 in Oral Squamous Cell Carcinoma. Oral Science International. 2007:38-44.
133. Schmidt M, Schler G, Gruensfelder P, Muller J and Hoppe F. Urokinase receptor up-regulation in head and neck squamous cell carcinoma. Head Neck. 2000; 22:498-504.
134. Baker EA, Leaper DJ, Hayter JP and Dickenson AJ. Plasminogen activator system in oral squamous cell carcinoma. Br J Oral Maxillofac Surg. 2007; 45:623-627.
135. Pacheco MM, Kowalski LP, Nishimoto IN and Brentani MM. Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs. Head Neck. 2002; 24:24-32.
136. Leto G, Tumminello FM, Gebbia N, Bazan V, Tomasino RM, Dardanoni G and Russo A. Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: clinical implications. Int J Biol Markers. 2001; 16:245-249.
137. Nisa L, Aebersold DM, Giger R, Caversaccio MD, Borner U, Medova M and Zimmer Y. Profiling invasiveness in head and neck cancer: recent contributions of genomic and transcriptomic approaches. Cancers (Basel). 2015; 7:585-597.
138. Du B, Leung H, Khan KM, Miller CG, Subbaramaiah K, Falcone DJ and Dannenberg AJ. Tobacco smoke induces urokinase-type plasminogen activator and cell invasiveness: evidence for an epidermal growth factor receptor dependent mechanism. Cancer Res. 2007; 67:8966-8972.
139. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku T and Takagi R. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer. 2003; 106:683-689.
140. Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S and Yamamoto E. Expression of urokinasetype plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors. Oncol Rep. 2011; 26:1555-1560.
141. Strojan P, Budihna M, Smid L, Vrhovec I and Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res. 2000; 20:3975-3981.
142. Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ and Lingen MW. Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res. 2003; 63:555-559.
143. Duffy MJ, McGowan PM, Harbeck N, Thomssen C and Schmitt M. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014; 16:428.
144. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmuller S, Kiechle M, Janicke F and Thomssen C. Tenyear analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013; 49:1825-1835.
145. Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C and Harbeck N. Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. BMC Cancer. 2011; 11:140.
146. Kolben T, Augustin D, Armbrust R, Kolben TM, Degenhardt T, Burgmann M, Goess C, Ditsch N, Kates R, Harbeck N and Wuerstlein R. Impact of guideline-based use of uPA/PAI-1 on patient outcome in intermediate-risk early breast cancer. Breast Cancer Res Treat. 2016; 155:109-115.
147. Placencio VR and DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res. 2015; 75:2969-2974.
148. Fortenberry YM. Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). Expert Opin Ther Pat. 2013; 23:801-815.
149. Rockway TW, Nienaber V and Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des. 2002; 8:2541-2558.
150. Rupin A, Gaertner R, Mennecier P, Richard I, Benoist A, De Nanteuil G and Verbeuren TJ. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood. Thromb Res. 2008; 122:265-270.
151. Fjellstrom O, Deinum J, Sjogren T, Johansson C, Geschwindner S, Nerme V, Legnehed A, McPheat J, Olsson K, Bodin C, Paunovic A and Gustafsson D. Characterization of a small molecule inhibitor of plasminogen activator inhibitor type 1 that accelerates the transition into the latent conformation. J Biol Chem. 2013; 288:873-885.
152. Simone TM, Higgins SP, Higgins CE, Lennartz MR and Higgins PJ. Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease. J Mol Genet Med. 2014; 8.
153. Lin Z, Jensen JK, Hong Z, Shi X, Hu L, Andreasen PA and Huang M. Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist. Chem Biol. 2013; 20:253-261.
154. Placencio VR, Ichimura A, Miyata T and DeClerck YA. Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity. PLoS One. 2015; 10:e0133786.
155. Masuda T, Hattori N, Senoo T, Akita S, Ishikawa N, Fujitaka K, Haruta Y, Murai H and Kohno N. SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Mol Cancer Ther. 2013; 12:2378-2388.
156. Gomes-Giacoia E, Miyake M, Goodison S and Rosser CJ. Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Mol Cancer Ther. 2013; 12:2697-2708.
157. Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata T and Yaegashi N. Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther. 2015; 16:253-260.
158. Leik CE, Su EJ, Nambi P, Crandall DL and Lawrence DA. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost. 2006; 4:2710-2715.
159. Frederickson M, Callaghan O, Chessari G, Congreve M, Cowan SR, Matthews JE, McMenamin R, Smith DM, Vinkovic M and Wallis NG. Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008; 51:183-186.
160. Meyer JE, Brocks C, Graefe H, Mala C, Thans N, Burgle M, Rempel A, Rotter N, Wollenberg B and Lang S. The Oral Serine Protease Inhibitor WX-671-First Experience in Patients with Advanced Head and Neck Carcinoma. Breast Care (Basel). 2008; 3:20-24.
161. Goldstein LJ, Stemmer SM, Schmalfeldt B, Gottschalk N, Cardoso F, Dushkin H, Mala C, Uebler N, Bevan P and Harbeck N. Phase II, two-arm, double-blind, multicenter, randomized study of the combination of oral WX-671 plus capecitabine versus capecitabine in first-line HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 2010; 28(suppl; abstr TPS131.
162. Heinemann V, Ebert MP, Pinter T, Bevan P, Neville G and Mala C. Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer. Journal of Clinical Oncology. 2010; 28, 2010(suppl; abstr 4060).